DNAnexus, a leading provider of cloud-based biomedical data analysis software serving the life sciences community, today announced a $200 million financing round to accelerate the global adoption of its technology, translating the world's complex multi-omics and clinical data into tangible insights and personalized treatments. The round was led by funds managed by Blackstone Growth (BXG), with participation from existing investors Northpond Ventures, GV, Perceptive Advisors, Innovatus Capital Partners, and Foresite Capital.

To improve human health, researchers and clinicians need to access complex and sensitive biomedical data and innovative technologies that can enable novel insights. However, these data are often incompatible or difficult to process. DNAnexus is the leading bioinformatics company that facilitates secure access and utilization of biomedical data while supporting collaboration across internal and external teams. From providing an end-to-end integrated diagnostic R&D and production bioinformatics platform that enables national biobank biomedical initiatives to providing pharmaceutical companies with a multi-omics data science platform for new target drug discovery, DNAnexus empowers the healthcare and life sciences industry to transform how they leverage biomedical data to accelerate scientific discoveries and deliver better patient care.